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The investigation of the fine specificities  of antinuclear  antibodies (ANAs) 
has been fruitful  in terms of the nosology and immunopathogenesis  of human 
autoimmune  syndromes.  Particular  reactivities serve as "markers,"  in that 
patients with certain syndromes have a much higher incidence of such ANAs 
than do patients with other diseases. In this category is the almost exclusive 
presence in certain systemic lupus erythematosus  (SLE) patients of reactivity 
against  the nuclear acidic protein Sin. Reactivity to Sm  can be detected by 
precipitation in agar, complement fixation,  or passive hemagglutination  (1, 2). 
Auteimmune  mouse strains have also  provided a fertile  field  for the investi- 
gation of  the basic phenomena  of self-reactivity.  In particular, the NZB  strain 
and its hybrid NZB  × NZW  have been considered excellent models for human 
SLE and have therefore been studied in great detail (3, 4). 
In addition, Murphy  et al at The Jackson Laboratory, Bar Harbor, Maine, 
have developed several new inbred mouse strains that spontaneously develop 
SLE-like  syndromes  (5, 6). These  are the BXSB  strain, which has a male 
dominant disease characterized by little  antinative DNA  antibody; the MRL/I, 
which  develops  massive,  nonmalignant  lymphadenopathy,  associated  with 
enormous  increases  in serum  immunoglobulin  levels and  fulminant  renal 
disease; and the MRL/n,  which does not develop SLE-like disease until well 
into  the 2nd yr of  life,  but like  the MRL/I develops high titers  of  ANA  and fatal 
glomerulonephritis.  The MRL/I differs  from MRL/n  in only about 10% of its 
genome, including the gene responsible for  the MRL/rs lymphoproliferation. 
In the current study, we have used the technique of  double immunodiffusion 
(ID)  in agarose with standard human reference sera (of  known ANA  specificity) 
to survey a large number of  mice from the NZB, NZB  x NZW,  MRL/I, MRL/n, 
BXSB, and other strains. We report here the finding of  the anti-Sin "marker" 
antibody almost uniquely in the MRL/I and MRL/n animals. These two related 
strains may serve as experimental models to explore the mechanism stimulat- 
ing the production of  this unique autoantibody in SLE. 
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Materials and Methods 
Mice.  NZB and NZW, originally obtained from Dr.  M.  Bielschowsky (University of Otago 
Medical School,  Dunedin, New Zealand), have been bred at  our institution  since  1965. 
BXSB, MRL/I, and MRL/n mice were originally  obtained from The Jackson Laboratory, and 
have been bred at our institution  since  1976.  A compendium of  our initial  experience with these 
new strains,  in comparison with the New Zealand strains,  will  be published separately.  I  Mice 
were bled either  by retro-orbital  puncture under ether anesthesia, or were exsanguinated 
through the axillary  vessels.  Sera were frozen  no more than once before  assay.  In early  testing, 
pools  of  sera from two to five  animals were used and tabulated as single  animal experiments. 
The  great majority of  tests  were done on sera from individual  animals. 
Doable Immunodiffusion Assay.  Preliminary studies  were done with 0.4% agarose in phos- 
phate-(0.01  M) buffered saline,  pH 7.2,  with 0.1% NaN3 in 100-ram glass  Petri  dishes.  Sera of 
human origin  containing precipitating  antibodies  were used  to identify  the Sin,  nuclear ribonu- 
cleoprotein,  SjSgren's  B, and DNA  antigens, and had been characterized  according to methods 
described  previously (1, 7-9).  Because of  the limited  amount of  individual  mouse sara available, 
we mostly used wells  4 mm  in diameter, 3 mm  apart,  and holding 25 /A. 
Antigens.  A soluble  phosphate buffer  extract  of  a commercial rabbit  thymus extract (RTE, 
Pel-Freeze  Bio-Animals, Inc.,  Rogers, Ark.) was  used  as  a source  of  nuclear antigen as  previously 
described (10).  Sera were also  screened against an extract  of  a human lymphoblastoid cell  line 
(Wil2)  (8),  but no strong lines  were seen that were not also  formed against RTE. 
Precipitin  Curves.  Quantitative precipitin  reactions were carried out with 25 or 50 ~l of 
serum and equal volumes of serial  two-fold  dilutions  of RTE that had been predigested with 
RNAse (10).  Samples  were incubated at  37°C for  15  rain  and  then  at  4°C  for  4  days.  After  washing 
three  times  in  cold  phosphate-buffered saline,  precipitates  were redissolved  in 1  ml of  I N NaOH 
and the optical  density at 280 nm determined. Appropriate corrections  were made for antigen- 
only and serum-only  controls.  Results obtained were standardized to 1 ml serum. 
Results 
Strain Survey.  The most prominent reactivity found against RTE was anti- 
Sm (Fig.  1).  With the sole exception of one old NZB  ×  NZW female pool, this 
specificity was found only in the MRL/1 and MRL/n strains (Table I). All of the 
NZB,  BXSB  or animals of normal strains,  and 36/37  NZB  x  NZW showed no 
evidence  of anti-Sm.  The  patterns  of reactivity  regarding  age and sex in the 
two  positive  strains  were  of  interest  (Fig.  2).  The  MRL/1  strain  develops 
rapidly  progressive  disease  beginning  about  4  mo  of  age,  characterized  by 
lymphadenopathy,  hypergammaglobulinemia,  antibodies  to  DNA,  ANA,  and 
fatal glomerulonephritis.  The females show a  slightly more severe disease.  In 
our immunodiffusion assay, none of the animals of either sex showed any anti- 
Sm reactivity  before  the  age  of 4  mo.  Of the  4-  and  5-mo animals,  many  of 
them  moribund,  the  males  gave  a  higher  percentage  of reactivity  than  the 
females (37% vs. 10%). The combined percentage positivity (males plus females, 
all  greater  than  3  mo of age) for the sick  animals of this strain  is  24%. This 
number falls in the range of positivity for human SLE patients  (20-30%,  2). 
The MRL/n mice have a median survival for the females of 17 mo and for the 
males of 23 mo.  We have not yet had the opportunity to investigate  in detail 
the parameters of their  autoimmune syndrome, but based on our preliminary 
data  and  that  of  Murphy  (unpublished  observations),  it  appears  that  the 
disease in the MRL/n is very similar to that of the MRL/1 except for its slower 
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Fro.  1.  Double immunodiffusion in 0.4% agarose of a pool of 4 mo male MRL/1 sera. RTE 
containing nuclear antigens and specific human reference antisera are in peripheral wells. 
Plate  was developed 2  days at  room temperature.  Note that  MRL/1  serum developed a 
strong precipitin line which fused completely with anti-Sm reference serum. 
time-course and the lack of the massive lymphadenopathy. A few of the MRL/n 
showed Sm reactivity before the age of 4 mo (Table I and Fig. 2). The degree of 
positivity in the MRL/n males and females at 4- to 5-mo of age is strikingly 
similar to that of the MRL/1.  After that age, it was not possible to determine 
incidence of anti-Sm in the  MRL/1  since most of the animals die from their 
disease.  The  anti-Sm  positivity of the  MRL/n  continues  to  rise,  with  the 
females eventually showing greater reactivity than the males (at 9-12  mo of 
age, females are 83% positive, while males are 57% positive). We have not yet 
had the opportunity to examine mice of greater than 1 yr of age. 
Other  Specificities.  One  NZB  x  NZW  ll-mo  female pool  reacted  with  a 
clear line of identity with our anti-RNP reference serum. Otherwise, although EISENBERG  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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SWain  Sex  Age  Number  tested  Pomtive 
mo  % 
MRLII  M  + F  I-3  24  0 
MRL/I  M  4-5  27  37 
MRLII  F  4-5  21  i0 
MRIMn  M  1-3  40  3 
MRL/n  F  1-3  38  5 
MRL/n  M  4-12  43  35 
MRL/n  F  4-12  62  45 
NZB  M  +  F  4-13  77  0 
NZB x NZW  M + F  1-17  37  3 
BXSB  M  +  F  2-12  44  0 
Others (NZW, HaICr, BALB/¢, C57BId6, I, 8m, 129)  M + F  1-12  41  0 
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FIG.  2.  Age  relationship of anti-Sin  reactivity  in  MRL  mice.  Open symbols represent 
MRL/n mice.  Numbers next to points indicate size of each age group tested.  MRL/1 mice 
are  shown by  the  closed  symbols at  4-5  mo  only,  as  all  younger  MRL/1  tested  were 
negative.  Circles represent females, triangles represent males. 
we occasionally saw strong lines which were not Sm, no other lines of identity 
were seen. This means that precipitating antibodies to Sj6gren's B antigen and 
DNA  are  probably not prominent in our mice.  Additional strong lines were 
seen particularly with the MRL/n sera.  Preliminary investigations show that 
these lines are not directed against soluble DNA-histone and that the antigen 
involved is sensitive to pepsin, but not to RNAse or DNAse. 
Further Studies.  Six ID-positive MRL/1 sera were subjected to immunoelec- 
trophoresis.  Five of the  sera  were strong enough reactors to give precipitin 
lines against the nuclear antigen (Fig. 3). In all cases the line observed had a 
gamma mobility somewhat more restricted than that of the whole serum IgG. 
This is similar to the experience with human anti-Sm sera processed the same 
way  (7). In  quantitative  precipitin  studies  we  found that  no  serum  tested 
contained more than 0.4 mg/ml of anti-Sm antibody protein. 
Discussion 
We have surveyed autoimmune mouse strains for the specificities of their 
anti-nuclear antibodies by double  immunodiffusion in  agarose,  an  approach 586  EISENBERG  ET  AL.  BRIEF  DEFINITIVE  REPORT 
Fro.  3.  Immunoelectrophoresis of MRL/1 serum in 0.5% agarose.  Both wells were filled 
with serum of a 4 mo male MRL/1 and electrophoresed at 42 V for 45 rain (anode at right). 
The  upper trough contained rabbit anti-mouse gamma globulin (heavy and light chain) 
and the lower trough RTE.  Patterns were developed at room temperature for 2 days. 
which has proven to be very productive as applied to human connective tissue 
diseases. The most prominent of our findings was a high percentage of reactivity 
with the  Sm  antigen in  the  MRL/1  and  MRL/n mice.  Outside  of these two 
strains, we have thus far found only a  single reactive sample, a pool of 11 mo 
old NZB ×  NZW females. We feel that the presence of this marker antibody in 
the MRL mice make them interesting for study as models of human SLE. On 
the other hand, we do not understand why anti-Sin reactivity is not commonly 
found  in  the  NZB  ×  NZW  mice,  as  their  disease  in  many  other  respects 
resembles that of the MRL. The NZB and BXSB mice, on the other hand, have 
somewhat  different  syndromes,  with  lower  levels  of  ANA  and  anti-DNA 
antibodies.' 
Beyond its status as a marker antibody, the immunopathological significance 
of anti-Sm antibody both in man and mice is unclear at this time. Although we 
have yet to study this question systematically, we have not noticed a peculiarity 
of the disease pattern of the anti-Sm positive animals, as has been suggested in 
humans (11). In the MRL/1 mice, the appearance of anti-Sm is detected at an 
age  (4 mo) when the animals' disease is already rampant.  In the MRL/n, on 
the other hand, anti-Sm reactivity begins to appear at a  very early age (Fig. 
2), and is found in a majority of the animals by the time they become seriously 
ill. We have not yet been able to study this strain in detail, so that we cannot 
make any statements regarding the relationship of appearance of anti-Sm to 
other parameters of autoimmune disease. 
We realize, of course, that failure to detect anti-Sin reactivity in particular 
specimens may be the result of the insensitivity of the methods employed. We 
are currently attempting to develop a radioimmune assay that would permit us 
to look at the ~'negative" sera more closely. In this regard, it is interesting that 
in human SLE no low titer positives were found: sera were either very positive 
or completely negative (2). We have the impression, based on the strength of 
the precipitin lines observed,  that with the MRL/1 all positive animals were EISENBERG  ET  AL.  BRIEF  DEFINITIVE  REPORT  587 
strongly positive.  We have not seen a  single case of a  faint ID line with these 
mice.  In the case of the  MRL/n  mice,  on the other hand,  particularly in the 
very young animals, we have frequently noted weak, though clear, immunopre- 
cipitin lines. A  radioimmune assay would permit us to look at this situation in 
a  more quantitative way. 
Our  data  at  this  point  do not permit  us  to  speculate on the  nature  of the 
immunological aberration which causes production of anti-Sm antibody in the 
MRL/1 and MRL/n strains,  nor on the pathogenetic role of this antibody. The 
observation that anti-Sm antibody appears to be somewhat restricted to certain 
strains  of  mice  is  interesting,  in  view  of  published  reports  that  anti-Sm 
antibody is highly restricted to human  SLE and rarely found in other human 
autoimmune diseases.  The availability of animal models may make it possible 
to explore approaches to some of these problems. 
Received for publication 7 October 1977. 
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